Umoja Biopharma Stock
HealthTechLooking to sell Umoja Biopharma stock or options?
Umoja Biopharma is a provider of advanced immunotherapies designed to revolutionize cancer treatment and enhance patient quality of life. The company's innovative cellular immunotherapy platform employs gene therapy to specifically target cancer cells. This platform can be delivered to any patient, with any type of tumor, at any given time. It works by directly, safely, and controllably attacking cancer, which empowers healthcare professionals to protect patients by generating and harnessing a robust immune response within the body.
Presight Capital, Myeloma Investment Fund, RTW Investments, MPM BioImpact, Seattle Children's Hospital, Emerson Collective, Casdin Capital, WRF Capital, ARK Venture Fund, Cormorant Asset Management, Double Point Ventures, SoftBank Investment Advisers, University of Minnesota, CaaS Capital Management, Temasek Holdings, ARK Investment Management, Alexandria Venture Investments, K2 HealthVentures, Purdue Ventures, Qiming Venture Partners USA, Third Point Ventures, Leerink Partners, DCVC Bio, AbbVie Ventures.